BioCardia (BCDA) CEO Peter Altman adds 1,000 shares in open-market buys

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman reported open-market purchases of company stock. He bought a total of 1,000 shares of BioCardia common stock in two transactions at a weighted average price of $1.23 per share, increasing his direct holdings to 275,766 shares following these trades.

Insider Trade Summary

Net Buyer: 1,000 shares ($1,230)

Net Buy 2 txns

Insider Altman Peter

Role President and CEO

Bought 1,000 shs ($1K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	400	$1.23	$492.00
Purchase	Common Stock	600	$1.23	$738.00

Holdings After Transaction: Common Stock — 275,766 shares (Direct, null)

Footnotes (1)

This transaction was executed in multiple trades ranging from $1.22 to $1.27 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price. This transaction was executed in multiple trades ranging from $1.21 to $1.24 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Key Figures

Total shares purchased: 1,000 shares Weighted average purchase price: $1.23 per share Shares after final transaction: 275,766 shares +4 more

7 metrics

Total shares purchased 1,000 shares Open-market common stock buys reported in Form 4

Weighted average purchase price $1.23 per share Reported for the two common stock transactions

Shares after final transaction 275,766 shares Direct ownership following April 21, 2026 trade

Shares bought on 2026-04-21 400 shares Common stock open-market purchase at $1.23 per share

Shares bought on 2026-04-20 600 shares Common stock open-market purchase at $1.23 per share

Price range for first trade $1.22–$1.27 per share Footnote F1 price range for April 21, 2026 purchases

Price range for second trade $1.21–$1.24 per share Footnote F2 price range for April 20, 2026 purchases

Key Terms

open-market purchase, weighted average per share sales price, reporting person, Form 4

4 terms

open-market purchase financial

"transaction_action: "open-market purchase" for both common stock transactions"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

reporting person regulatory

"The Reporting Person hereby undertakes to provide upon request to the SEC staff"

Form 4 regulatory

"INSIDER FILING DATA (Form 4) describes the insider transactions"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

04/22/2026 - 05:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last)

(First)

(Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE

CALIFORNIA

94085

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/20/2026		P		600⁽¹⁾	A	$1.23⁽¹⁾	275,366	D
Common Stock	04/21/2026		P		400⁽²⁾	A	$1.23⁽²⁾	275,766	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $1.22 to $1.27 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

2. This transaction was executed in multiple trades ranging from $1.21 to $1.24 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did BioCardia (BCDA) report in this Form 4?

BioCardia reported that President and CEO Peter Altman made two open-market purchases of common stock, totaling 1,000 shares. These trades occurred on April 20 and April 21, 2026, and were executed at a weighted average price of $1.23 per share.

How many BioCardia (BCDA) shares does Peter Altman hold after these trades?

After the reported purchases, Peter Altman directly holds 275,766 shares of BioCardia common stock. This figure reflects his position following the final transaction on April 21, 2026, as disclosed in the Form 4 insider ownership table.

At what prices did Peter Altman buy BioCardia (BCDA) shares?

The Form 4 shows a reported weighted average purchase price of $1.23 per share. Footnotes explain individual trades were executed in ranges of $1.22 to $1.27 per share and $1.21 to $1.24 per share on the respective transaction dates.

Were Peter Altman’s BioCardia (BCDA) purchases open-market transactions?

Yes. The filing classifies both transactions as open-market purchases of BioCardia common stock. The code "P" and the description "Purchase in open market or private transaction" confirm these were standard market buys rather than derivative exercises or gifts.

Does the BioCardia (BCDA) Form 4 mention derivative securities or options?

No derivative transactions are listed in this Form 4. The derivative summary section is empty, indicating the reported activity pertains only to non-derivative common stock purchases and does not involve options, warrants, or other derivative securities.